THE STUDY OF THE TYPES OF INHERITANCE OF PLANT HEIGHT OF WINTER SOFT WHEAT HYBRIDS F2

The plant height is an important qualitative trait. It affects productivity and resistance to lodging of the crop. The efficiency of the selection of the plants with necessary stem height depends on the amount and quality of the accumulated information about genetic system of trait control. The article deals with the results of the study of winter soft wheat hybrids of the second generation, allelic differences of the genes of plant height of four varieties. There were studied 10 hybrids F2 obtained from diallel hybridization of the varieties and lines of winter soft wheat 'Bunchuk', 'Kipchak', '1421/06' (with a working name Luiza) and '696/98' (with a working name Emma). The genetic analysis of the quantitative trait of a stem height was carried out with the help of the computer programs Gen-3 and Plygen A. The analysis determined the partial and incomplete dominance of the large value of the trait, the degree of the dominance (hp) varied from 0.12 to 0.95. It was established that the plant height differences among the studied varieties of winter soft wheat were caused by the small amount of the genes with various strength, i.e. 1-3 pairs, responsible for the transfer of the studied trait. The strength of the gene was 4, 7 and 15 cm. The varieties 'Bunchuk' and 'Kipchak', 'Kipchak' and 'Luiza', 'Luiza' and 'Emma' differed from each other according to the allelic state of one locus. The varieties 'Bunchuk' and 'Luiza', 'Kipchak' and 'Emma' differed from each other according to the allelic state of two locuses. The varieties 'Bunchuk' and 'Emma' differed from each other according to the allelic state of three locuses

Clinical Case: Tuberculous Myopericarditis in the Cardiology Practice

Pericarditis is not enough researched and described in literature despite the emergence of a large quantity of up-to-date laboratory and instrumental methods of verification. The main problem is that  pericarditis might be a sign of many infectious and non-infectious diseases. It is quite difficult to define the etiopathogenetic reason of process. The article presents a clinical observation of a 53 years old mail patient with paroxysms of atrial flutter, non-symptomatic febrile fever, arthralgia and  signs of exudative pericarditis, which were  manifested after  the acute  viral infection. The symptoms have been lasting for 8 months before the patient’s hospitalization. In lab tests anemia, leucopenia, increase level of platelets and increase antinuclear antibody level were found. Several conceptions were considered: cancer with paraneoplastic syndrome, systemic disease, infectious process, myeloma, which were subsequently excluded. Due to the fact that pericardial effusion may often be associated with tuberculosis Diaskin test and T-SPOT were performed and they appeared to be positive. After several months of antituberculous treatment temperature normalized, atrial flutter episodes and arthralgia diminished. So empirically and  laboratory tuberculous pericarditis with atypical manifestation was  confirmed. The particularity of this observation is a nontypical clinical picture and the absence of a primary focus of infection. That is why the clinicians could not define the diagnosis rapidly

Safety of dabigatran in patients with atrial fibrillation and chronic kidney disease: pharmacokinetic and pharmacogenetic aspects

Background: despite well-studied safety profile of dabigatran its interactions with genetic polymorphism parameters are poorly understood, especially in patients with moderate chronic kidney disease (CKD). This study was aimed to evaluate relationships between CES1 and ABCB1 polymorphism, dabigatran trough plasma concentration (DTPC) and bleeding events in patients with AF and CKD.Methods: patients with atrial fibrillation (AF) and stage 3 CKD treated with dabigatran 110mg or 150 mg have been included in the study. Real-time PCR was used to evaluate single nucleotide polymorphisms (SNPs) of the ABCB1 gene (rs1045642, rs4148738) and CES1 gene (rs2244613). A plasma trough concentration/dose (C/D) ratio was used as a pharmacokinetic index.Results: a total of 60 patients, aged 51–89 years (median age 76 years) were evaluated. Compared with patients given 150 mg twice a day, those given 110 mg twice a day were older (79 vs 67.5, p < 0.0001) and had lower creatinine clearance (CrCl) (50.5 vs 60.5 mL/min/1.73 m2, p = 0.015). We found C/D values to have high interindividual variability (mean 365.9 ± 290.4 μg/ml: mg/day, range 23.64-1452.73). Individuals with CKD 3B had higher concentration of dabigatran compared with those with 3A stage (488.7 ± 232.3 vs 332 ± 297.8 μg/ml : mg/day, p = 0.02). Consequently, there also was negative correlation of C/D with CrCl (r = -0.4, p = 0.0015). Evaluated SNPs (rs1045642, rs4148738, and rs2244613) did not affect C/D values (H test p > 0.05).Conclusions: C/D values were significantly higher in patients with CKD 3B stage and those treated with dabigatran 110 mg. There was no influence of aforementioned SNPs on dabigatran trough concentrations and clinical outcomes

New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants

Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban and dabigatran for different indications: atrial fibrillation, endoprosthesis of large joints of lower limbs.Material and methods. The study enrolled 29 patients (17 patients received dabigatran and 12 –rivaroxaban), who had hemorrhagic complications during taking direct oral anticoagulants. To find new pharmacogenetic biomarkers of bleeding risk, a next generation sequencing (NGS) was performed for selected candidate genes.Results. Among the patients with bleeding who received dabigatran, 13 variants of the nucleotide sequence showed statistically significant deviation from the population values: 11 in the CES1 gene and 2 in the ABCB1 gene. Among the patients with bleeding who received rivaroxaban, 7 variants of nucleotide sequence showed significant deviation: 4 in the ABCG2 gene, 2 in the CYP3A4 gene, and 1 in the ABCB1 gene.Conclusion. The identified in this study polymorphisms of candidate genes ABCB1, ABCG2, CES1, CYP3A4 were associated with the risk of bleeding in patients taking rivaroxaban and dabigatran. It makes an important contribution to the pharmacogenetics of direct oral anticoagulants and require additional assessment of clinical significance in further studies